學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Serum Institute of India: COVID-19 Vaccine Pricing
內容大綱
Serum Institute of India (SII) was the world's largest manufacturer of vaccines and had signed an agreement to produce the Oxford vaccine, a top five candidate. The chief executive officer, Adar Poonawala, had announced in late July 2020 that the government of India had agreed to buy two doses of the vaccine, at a price of US$13 per dose. In early August, two developments caused Adar to revisit SII's initial pricing decision. The first development was that Russia had announced it had developed a vaccine that was ready for mass distribution in early October-two months ahead of SII. The second development was that Johnson & Johnson had announced a price of US$10 per dose. The case outlines the decisions facing SII concerning the pricing strategy and pricing dynamics for their COVID-19 vaccine.